{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T16:26:00Z","timestamp":1786638360028,"version":"build-2736575974"},"reference-count":64,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,13]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Biosimilars used in hematology have been at the forefront of biosimilar development since the first US approval in 2015 of a filgrastim product, with &amp;gt;80 now licensed by the US Food and Drug Administration (FDA). Developers traditionally submitted data from a comparative analytical assessment (CAA) and clinical studies, often including a comparative efficacy study (CES), to support demonstrating their product is \u201chighly similar\u201d to and has \u201cno clinically meaningful differences\u201d from its reference product (RP). However, growing scientific confidence in the analytical comparisons between biosimilars and their RP included in the CAA has prompted the FDA and global regulators to reconsider the utility of CESs. Recently, the FDA published updated recommendations on the need for a CES in biosimilar programs. As approvals for hematologic biosimilars span the entire history of FDA biosimilar development across a breadth of patient ages and diseases, reexamining these programs provides valuable insights into the evolving role of the CES in the past and its role in the future. In this review, we present a historical overview of the development programs for all FDA-approved hematologic biosimilars in the context of an emerging global consensus recognizing that the CAA is more sensitive than the CES for predicting biosimilarity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2025031673","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T11:28:29Z","timestamp":1778585309000},"page":"807-817","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Biosimilars approved for hematology use: lessons from comparative efficacy studies and comparative analytical assessments"],"prefix":"10.1182","volume":"148","author":[{"given":"Thomas M.","family":"Herndon","sequence":"first","affiliation":[{"name":"Office of Therapeutic Biologics and Biosimilars, Office of New Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina N.","family":"Brahme","sequence":"additional","affiliation":[{"name":"Office of Therapeutic Biologics and Biosimilars, Office of New Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Stacey","family":"Ricci","sequence":"additional","affiliation":[{"name":"Office of Therapeutic Biologics and Biosimilars, Office of New Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2026081311213683800_bib1","unstructured":"U.S. Food and Drug Administration\n          . Biosimilars. Accessed 30 November 2025. https:\/\/www.fda.gov\/drugs\/therapeutic-biologics-applications-bla\/biosimilars."},{"key":"2026081311213683800_bib2","unstructured":"Association for Accessible Medicines\n          . 2025 U.S. generic & biosimilar medicines savings report. Accessed 3 March 2026. https:\/\/accessiblemeds.org\/wp-content\/uploads\/2025\/09\/AAM-2025-Generic-Biosimilar-Medicines-Savings-Report-WEB.pdf."},{"key":"2026081311213683800_bib3","unstructured":"Biosimilars Forum\n          . Biosimilars are a free-market competition solution to lower drug costs for millions of Americans. Accessed 3 March 2026. https:\/\/biosimilarsforum.org\/wp-content\/uploads\/Biosimilars-are-a-Free-Market-Competition-Solution.pdf."},{"key":"2026081311213683800_bib4","unstructured":"U.S. Department of Health and Human Services\n          . Fact Sheet: bringing lower-cost biosimilar drugs to American patients. Accessed 3 March 2026. https:\/\/www.hhs.gov\/press-room\/fact-sheet-bringing-lower-cost-biosimilar-drugs-to-american-patients.html#:\u223c:text=Biosimilars%20are%20the%20generic%20version%20of%20expensive%2C,with%20$20%20billion%20saved%20in%202024%20alone%20."},{"key":"2026081311213683800_bib5","unstructured":"IQVIA Institute\n          . The global use of medicines 2023 outlook to 2027. Accessed 3 March 2023. https:\/\/www.iqvia.com\/-\/media\/iqvia\/pdfs\/library\/presentations\/presentation_global_meds_2023_webinar.pdf."},{"issue":"8","key":"2026081311213683800_bib6","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/d41573-025-00101-2","article-title":"The US biosimilars market after one decade","volume":"24","author":"Chaudhari","year":"2025","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"2026081311213683800_bib7","first-page":"e161","article-title":"First biosimilar drug approved in the USA","volume":"16","author":"Burki","year":"2015","journal-title":"Lancet Oncol"},{"issue":"1","key":"2026081311213683800_bib8","first-page":"19","article-title":"Zarxio (Filgrastim-sndz): the first biosimilar approved by the FDA","volume":"42","author":"Awad","year":"2017","journal-title":"P T"},{"key":"2026081311213683800_bib9","unstructured":"U.S. Food and Drug Administration\n          . Biosimilar product information. Accessed 3 March 2026. https:\/\/www.fda.gov\/drugs\/biosimilars\/biosimilar-product-information."},{"issue":"12","key":"2026081311213683800_bib10","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1007\/s12325-016-0431-5","article-title":"Awareness, knowledge, and perceptions of biosimilars among specialty physicians","volume":"33","author":"Cohen","year":"2017","journal-title":"Adv Ther"},{"key":"2026081311213683800_bib11","unstructured":"U.S. Food and Drug Administration\n          . Scientific considerations in demonstrating biosimilarity to a reference product. Accessed 3 March 2026. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/scientific-considerations-demonstrating-biosimilarity-reference-product-updated-recommendations."},{"issue":"1","key":"2026081311213683800_bib12","first-page":"102","article-title":"Factors affecting health care provider knowledge and acceptance of biosimilar medicines: a systematic review","volume":"25","author":"Leonard","year":"2019","journal-title":"J Manag Care Spec Pharm"},{"issue":"11","key":"2026081311213683800_bib13","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1634\/theoncologist.2018-0066","article-title":"Barriers to oncology biosimilars uptake in the United States","volume":"23","author":"Nabhan","year":"2018","journal-title":"Oncologist"},{"key":"2026081311213683800_bib14","unstructured":"U.S. Food and Drug Administration\n          . Scientific considerations in demonstrating biosimilarity to a reference product: updated recommendations for assessing the need for comparative efficacy studies. Accessed 1 December 2025. https:\/\/www.fda.gov\/media\/189366\/download."},{"key":"2026081311213683800_bib15","unstructured":"Hegel GWF. The Phenomenology of Spirit. Pinkard T, trans-ed\n          . Cambridge University Press; 2018. Accessed 9 October 2025. https:\/\/files.libcom.org\/files\/Georg%20Wilhelm%20Friedrich%20Hegel%20-%20The%20Phenomenology%20of%20Spirit%20(Terry%20Pinkard%20Translation).pdf."},{"issue":"11","key":"2026081311213683800_bib16","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1016\/j.drudis.2020.09.006","article-title":"Streamlined approval of biosimilars: moving on from the confirmatory efficacy trial","volume":"25","author":"Bielsky","year":"2020","journal-title":"Drug Discov Today"},{"issue":"1","key":"2026081311213683800_bib17","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/cpt.2785","article-title":"A data driven approach to support tailored clinical programs for biosimilar monoclonal antibodies","volume":"113","author":"Guillen","year":"2023","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"2026081311213683800_bib18","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s40259-023-00631-4","article-title":"Do the outcomes of clinical efficacy trials matter in regulatory decision-making for biosimilars?","volume":"37","author":"Kirsch-Stefan","year":"2023","journal-title":"BioDrugs"},{"issue":"3","key":"2026081311213683800_bib19","first-page":"225","article-title":"Survey of data package and sample size of comparative clinical studies for biosimilar developments from PMDA assessments","volume":"38","author":"Kuribayashi","year":"2024","journal-title":"Pharmaceut Med"},{"key":"2026081311213683800_bib20","author":"World Health Organization","year":"2022"},{"issue":"5","key":"2026081311213683800_bib21","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s40259-025-00733-1","article-title":"Analytical data and single-dose PK are sufficient to conclude comparable immunogenicity for biosimilars: an ustekinumab case study","volume":"39","author":"Schiestl","year":"2025","journal-title":"BioDrugs"},{"key":"2026081311213683800_bib22","unstructured":"U.S. Food and Drug Administration\n          . Clinical pharmacology data to support a demonstration of biosimilarity to a reference product. Accessed 14 May 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2025\/761024Orig1s021ltr.pdf."},{"issue":"14","key":"2026081311213683800_bib23","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1056\/NEJMoa040528","article-title":"Pure red-cell aplasia and epoetin therapy","volume":"351","author":"Bennett","year":"2004","journal-title":"N Engl J Med"},{"key":"2026081311213683800_bib24","author":"U.S. Food and Drug Administration","year":"2016"},{"issue":"10","key":"2026081311213683800_bib25","doi-asserted-by":"crossref","first-page":"e0292231","DOI":"10.1371\/journal.pone.0292231","article-title":"Safety outcomes when switching between biosimilars and reference biologics: a systematic review and meta-analysis","volume":"18","author":"Herndon","year":"2023","journal-title":"PLoS ONE"},{"issue":"2","key":"2026081311213683800_bib26","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s40259-017-0210-0","article-title":"Interchangeability of biosimilars: a European perspective","volume":"31","author":"Kurki","year":"2017","journal-title":"BioDrugs"},{"issue":"11","key":"2026081311213683800_bib27","doi-asserted-by":"crossref","first-page":"e543","DOI":"10.1016\/S2352-3026(18)30157-1","article-title":"Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial","volume":"5","author":"Ogura","year":"2018","journal-title":"Lancet Haematol"},{"issue":"15s","key":"2026081311213683800_bib28","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2217\/fon-2017-0153","article-title":"An introduction to biosimilar cancer therapeutics: definitions, rationale for development and regulatory requirements","volume":"13","author":"Buske","year":"2017","journal-title":"Future Oncol"},{"issue":"2","key":"2026081311213683800_bib29","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s40259-019-00398-7","article-title":"A randomized, double-blind, efficacy and safety study of PF-05280586 (a rituximab biosimilar) compared with rituximab reference product (MabThera\u00ae) in subjects with previously untreated CD20-positive, low-tumor-burden follicular lymphoma (LTB-FL)","volume":"34","author":"Sharman","year":"2020","journal-title":"BioDrugs"},{"key":"2026081311213683800_bib30","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1146\/annurev-med-051215-031022","article-title":"Biosimilars: the US regulatory framework","volume":"68","author":"Christl","year":"2017","journal-title":"Annu Rev Med"},{"issue":"14","key":"2026081311213683800_bib31","doi-asserted-by":"crossref","first-page":"4251","DOI":"10.3390\/molecules26144251","article-title":"NMR spectroscopy for protein higher order structure similarity assessment in formulated drug products","volume":"26","author":"Wang","year":"2021","journal-title":"Molecules"},{"key":"2026081311213683800_bib32","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.aca.2020.03.038","article-title":"FTIR spectroscopy as an analytical tool to compare glycosylation in therapeutic monoclonal antibodies","volume":"1112","author":"Derenne","year":"2020","journal-title":"Anal Chim Acta"},{"issue":"5","key":"2026081311213683800_bib33","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1002\/cpt.2783","article-title":"The mannose in the mirror: a reflection on the pharmacokinetic impact of high mannose glycans of monoclonal antibodies in biosimilar development","volume":"113","author":"Welch","year":"2023","journal-title":"Clin Pharmacol Ther"},{"key":"2026081311213683800_bib34","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jchromb.2019.04.031","article-title":"Glycan analysis for protein therapeutics","volume":"1120","author":"Yang","year":"2019","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"12","key":"2026081311213683800_bib35","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1056\/NEJMoa061648","article-title":"The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"355","author":"Hillmen","year":"2006","journal-title":"N Engl J Med"},{"issue":"12","key":"2026081311213683800_bib36","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1182\/blood-2005-04-1717","article-title":"Diagnosis and management of paroxysmal nocturnal hemoglobinuria","volume":"106","author":"Parker","year":"2005","journal-title":"Blood"},{"issue":"suppl 1","key":"2026081311213683800_bib37","doi-asserted-by":"crossref","first-page":"8660","DOI":"10.1182\/blood-2022-166722","article-title":"Efficacy and safety of biosimilar candidate ABP 959 as compared with eculizumab reference product in paroxysmal nocturnal hemoglobinuria [abstract]","volume":"140","author":"Kulasekararaj","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2026081311213683800_bib38","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/jha2.632","article-title":"A phase III, randomised, double-blind, multi-national clinical trial comparing SB12 (proposed eculizumab biosimilar) and reference eculizumab in patients with paroxysmal nocturnal haemoglobinuria","volume":"4","author":"Jang","year":"2023","journal-title":"eJHaem"},{"key":"2026081311213683800_bib39","unstructured":"U.S. Food and Drug Administration\n          . Drugs@FDA: FDA-approved drugs, biologic license application (BLA): 761333 (eculizumab-aeeb). 2024. Accessed 14 May 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2025\/761333Orig1s000ltr.pdf."},{"key":"2026081311213683800_bib40","unstructured":"U.S. Food and Drug Administration\n          . Drugs@FDA: FDA-approved drugs, biologic license application (BLA): 761340 (eculizumab-aagh). 2024. Accessed 14 May 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2025\/761340Orig1s015ltr.pdf."},{"key":"2026081311213683800_bib41","author":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use","year":"2004"},{"key":"2026081311213683800_bib42","first-page":"10","article-title":"Analytical similarity assessment of biosimilars: global regulatory landscape, recent studies and major advancements in orthogonal platforms","author":"Nupur","year":"2022","journal-title":"Front Bioeng Biotechnol"},{"key":"2026081311213683800_bib43","author":"U.S. Food and Drug Administration","year":"2019"},{"issue":"6","key":"2026081311213683800_bib44","doi-asserted-by":"crossref","first-page":"110115","DOI":"10.1016\/j.isci.2024.110115","article-title":"Monoclonal antibody biosimilars for cancer treatment","volume":"27","author":"Broer","year":"2024","journal-title":"iScience"},{"issue":"1","key":"2026081311213683800_bib45","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s41120-024-00096-x","article-title":"A controlled vocabulary and taxonomy for the submission of quality attributes for therapeutic proteins","volume":"10","author":"Welch","year":"2024","journal-title":"AAPS Open"},{"issue":"1","key":"2026081311213683800_bib46","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/s41392-024-01886-1","article-title":"Glycosylation: mechanisms, biological functions and clinical implications","volume":"9","author":"He","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"2026081311213683800_bib47","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1146\/annurev.biochem.73.011303.073752","article-title":"Roles of N-linked glycans in the endoplasmic reticulum","volume":"73","author":"Helenius","year":"2004","journal-title":"Annu Rev Biochem"},{"issue":"6","key":"2026081311213683800_bib48","doi-asserted-by":"crossref","first-page":"103771","DOI":"10.1016\/j.xphs.2025.103771","article-title":"Highly variable aggregation and glycosylation profiles and their roles in immunogenicity to protein-based therapeutics","volume":"114","author":"Sarsarshahi","year":"2025","journal-title":"J Pharm Sci"},{"key":"2026081311213683800_bib49","unstructured":"Authenticated US Government Information\n          . Food and Drug Omnibus Reform Act (FDORA) of 2022. HR7667. Accessed 14 May 2025. ."},{"key":"2026081311213683800_bib50","unstructured":"U.S. Food and Drug Administration\n          . Food and Drug Omnibus Reform Act (FDORA) of 2022. 2025. Accessed 14 May 2025. https:\/\/www.fda.gov\/regulatory-information\/selected-amendments-fdc-act\/food-and-drug-omnibus-reform-act-fdora-20222025."},{"issue":"3","key":"2026081311213683800_bib51","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s40259-020-00422-1","article-title":"The path towards a tailored clinical biosimilar development","volume":"34","author":"Schiestl","year":"2020","journal-title":"BioDrugs"},{"key":"2026081311213683800_bib52","unstructured":"European Medicines Agency (EMA)\n          . Reflection paper on a tailored clinical approach in biosimilar development. Accessed 14 May 2025. https:\/\/www.ema.europa.eu\/en\/reflection-paper-tailored-clinical-approach-biosimilar-development."},{"key":"2026081311213683800_bib53","volume-title":"Increasing the Efficiency of Biosimilar Development Programs - Reevaluating the Need for Comparative Clinical Efficacy Studies","author":"International Pharmaceutical Regulators Programme Biosimilars Working Group (BWG)","year":"2024"},{"issue":"6","key":"2026081311213683800_bib54","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3390\/ph18060779","article-title":"Scientific justification and policy recommendations to the US Food and Drug Administration for waiving comparative efficacy studies","volume":"18","author":"Niazi","year":"2025","journal-title":"Pharmaceuticals"},{"issue":"3","key":"2026081311213683800_bib55","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s40259-022-00533-x","article-title":"Regulatory evaluation of biosimilars: refinement of principles based on the scientific evidence and clinical experience","volume":"36","author":"Kurki","year":"2022","journal-title":"BioDrugs"},{"key":"2026081311213683800_bib56","unstructured":"IQVIA Institute\n          . Assessing the Biosimilar Void in the U.S. Achieving Sustainable Levels of Biosimilar Competition Feb 03, 2025: IQVIA Insititue. Accessed 3 March 2025. https:\/\/www.iqvia.com\/insights\/the-iqvia-institute\/reports-and-publications\/reports\/assessing-the-biosimilar-void-in-the-us."},{"key":"2026081311213683800_bib57","unstructured":"U.S. Food and Drug Administration\n          . Considerations in Demonstrating Interchangeability With a Reference Product: Update. Accessed 14 May 2025. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/considerations-demonstrating-interchangeability-reference-product-update."},{"key":"2026081311213683800_bib58","author":"National Administration of Medicines FaMTA, Argentina)","year":"2025"},{"key":"2026081311213683800_bib59","author":"Brazilian Health Regulatory Agency \u2013 Anvisa","year":"29, 2024"},{"key":"2026081311213683800_bib60","unstructured":"Saudi Food and Drug Authority\n          . SFDA draft general guideline on regulatory and scientific requirements for development and approval of biosimilar. 2025. https:\/\/www.sfda.gov.sa\/en."},{"key":"2026081311213683800_bib61","unstructured":"Health Canada\n          . Draft Guidance Document: Information and Submission Requirements for Biosimilar Biologic Drugs. 2025. Accessed 14 May 2025. https:\/\/www.canada.ca\/content\/dam\/hc-sc\/documents\/services\/drugs-health-products\/biologics-radiopharmaceuticals-genetic-therapies\/applications-submissions\/guidance-documents\/information-submission-requirements-biosimilar-biologic-drugs\/draft-biosimilars-guidance-external-consultation-eng.pdf."},{"key":"2026081311213683800_bib62","unstructured":"Medicines & Healthcare Products Regulatory Agency\n          . Guidance on the licensing of biosimilar products. 2025. Accessed 14 May 2025. https:\/\/go.csagroup.org\/l\/321721\/2025-08 05\/bv7bm?creative=&keyword=product%20certification&matchtype=p&network=o&device=c&msclkid=805fdf4824b219b23c46b54d549e88aa&utm_source=bing&utm_medium=cpc&utm_campaign=CERTIFICATION%20%7C%20Service%20-%20EN%20(IND)&utm_term=product%20certification&utm_content=GENERIC%20-%20Certification."},{"key":"2026081311213683800_bib63","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use\n          . M18: Framework for Determining the Utility of Comparative Efficacy Studies in Biosimilar Development Programs. 2025. Accessed 14 May 2025. https:\/\/database.ich.org\/sites\/default\/files\/ICH_M18_Final_Concept_Paper_MCEndorsed_2025_1119.pdf."},{"issue":"5","key":"2026081311213683800_bib64","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s40259-023-00619-0","article-title":"Future evolution of biosimilar development by application of current science and available evidence: the developer\u2019s perspective","volume":"37","author":"Cohen","year":"2023","journal-title":"BioDrugs"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/7\/807\/2537532\/blood_bld-2025-031673-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/7\/807\/2537532\/blood_bld-2025-031673-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T15:21:50Z","timestamp":1786634510000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/148\/7\/807\/568328\/Biosimilars-approved-for-hematology-use-lessons"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":64,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,8,13]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025031673","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8,13]]},"published":{"date-parts":[[2026,8,13]]}}}